{
    "clinical_study": {
        "@rank": "102345", 
        "acronym": "IVES", 
        "arm_group": {
            "arm_group_label": "Refresh Tears Lubricant Eye Drops (Allergan)", 
            "arm_group_type": "Experimental", 
            "description": "Artificial tears eye drops QID for 1 month"
        }, 
        "brief_summary": {
            "textblock": "Research indicates that many people who are being treated for glaucoma have dry eyes. The\n      purpose of this study is to test the use of artificial tears to alleviate dryness signs and\n      symptoms in people who are using medication to treat glaucoma. The study hypothesis is that\n      the use of artificial tears will result in an improvement in clinical signs and symptoms\n      associated with dry eyes."
        }, 
        "brief_title": "Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Glaucoma", 
            "Dry Eyes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Keratoconjunctivitis Sicca", 
                "Dry Eye Syndromes", 
                "Glaucoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 17 years of age and has full legal capacity to volunteer;\n\n          -  Has read and signed an information consent letter;\n\n          -  Is willing and able to follow instructions and maintain the appointment schedule;\n\n          -  Is a current non-contact lens wearer.\n\n          -  Has previously been diagnosed with primary open angle glaucoma and is currently being\n             treated with a topical therapeutic agent.\n\n          -  The glaucoma medication dosage and usage must have been the same for >6 months.\n\n          -  Shows a minimum score of 2 (sometimes) on the SESOD questionnaire.\n\n          -  Distance VA of at least 20/40 in each eye with current spectacle correction.\n\n        Exclusion Criteria:\n\n          -  Is participating in any concurrent clinical or research study;\n\n          -  Has any known active* ocular disease and/or infection; except primary open angle\n             glaucoma.\n\n          -  Has a systemic condition that in the opinion of the investigator may affect a study\n             outcome variable;\n\n          -  Is using any systemic or topical medications (with the exception of glaucoma\n             medication) that in the opinion of the investigator may affect a study outcome\n             variable;\n\n          -  Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;\n\n          -  Is pregnant, lactating or planning a pregnancy at the time of enrolment;\n\n          -  Has undergone refractive error surgery;\n\n          -  Is an employee of the Centre for Contact Lens Research;\n\n          -  Has taken part in another (pharmaceutical) research study within the last 30 days;\n\n          -  Is currently using artificial tears more than 3 times per day.\n\n               -  For the purposes of this study, active ocular disease is defined as infection or\n                  inflammation that requires therapeutic treatment. Mild (i.e. not considered\n                  clinically relevant) lid abnormalities (blepharitis, meibomian gland\n                  dysfunction, papillae), corneal and conjunctival staining and dry eye are not\n                  considered active ocular disease. Neovascularization and corneal scars are the\n                  result of previous hypoxia, infection or inflammation and are therefore not\n                  active."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "17 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682460", 
            "org_study_id": "18262"
        }, 
        "intervention": {
            "arm_group_label": "Refresh Tears Lubricant Eye Drops (Allergan)", 
            "description": "Eye drops QID for 1 month", 
            "intervention_name": "Refresh Tears Lubricant Eye Drops (Allergan)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tetrahydrozoline"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Waterloo", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "N2L 3G1"
                }, 
                "name": "Centre for Contact Lens Research, University of Waterloo"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients", 
        "other_outcome": {
            "description": "Participants will complete a standardized grading scales regarding their subjective ratings of comfort, dryness, burning and redness and comparisons will be made between the scores after 1 week and 1 month of artificial tear use with the baseline score.", 
            "measure": "Subjective ratings of comfort, dryness, burning and redness", 
            "safety_issue": "No", 
            "time_frame": "At baseline (dispensing visit) and 1 week and 1 month after using artificial tears"
        }, 
        "overall_official": {
            "affiliation": "University of Waterloo", 
            "last_name": "Lyndon Jones, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Canada: Ethics Review Committee", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Corneal and conjunctival staining will be assessed using slit lamp biomicroscopy.", 
                "measure": "Ocular surface staining", 
                "safety_issue": "No", 
                "time_frame": "At baseline (dispensing visit)"
            }, 
            {
                "description": "The time taken for the tear film to break up on the surface of the cornea will be measured using slit lamp biomicroscopy following fluorescein instillation .", 
                "measure": "Tear break up time with fluorescein", 
                "safety_issue": "No", 
                "time_frame": "At baseline (dispensing visit)"
            }, 
            {
                "description": "Corneal and conjunctival staining will be assessed using slit lamp biomicroscopy.", 
                "measure": "Ocular surface staining", 
                "safety_issue": "No", 
                "time_frame": "After 1 week"
            }, 
            {
                "description": "The time taken for the tear film to break up on the surface of the cornea will be measured using slit lamp biomicroscopy following fluorescein instillation .", 
                "measure": "Tear break up time with fluorescein", 
                "safety_issue": "No", 
                "time_frame": "After 1 week"
            }, 
            {
                "description": "Corneal and conjunctival staining will be assessed using slit lamp biomicroscopy.", 
                "measure": "Ocular surface staining", 
                "safety_issue": "No", 
                "time_frame": "After 1 month"
            }, 
            {
                "description": "The time taken for the tear film to break up on the surface of the cornea will be measured using slit lamp biomicroscopy following fluorescein instillation .", 
                "measure": "Tear break up time with fluorescein", 
                "safety_issue": "No", 
                "time_frame": "After 1 month"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682460"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Participants will complete a standardized questionnaire regarding their symptoms of dry eyes and comparisons will be made between the scores after 1 week and 1 month of artificial tear use with the baseline score.", 
            "measure": "Ocular surface disease index (OSDI) score", 
            "safety_issue": "No", 
            "time_frame": "At baseline (dispensing visit) and 1 week and 1 month after using artificial tears"
        }, 
        "source": "University of Waterloo", 
        "sponsors": {
            "collaborator": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Waterloo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}